Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.64 |
| ▸ | THRA | P10827 | 10/20 | 0.64 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890126 | 0.80 | GLRA1 (0.46) | THRBTHRAPLA2G4BRXRAPPARG | |
| SCHEMBL4890901 | 0.80 | THRB (0.69) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL5598887 | 0.79 | THRB (0.49) | THRBTHRARXRAPPARGALDH1A1 | |
| SCHEMBL13062425 | 0.78 | THRB (0.68) | THRBTHRAPLA2G4BRARARARB | |
| SCHEMBL4890007 | 0.78 | THRB (1.00) | THRBTHRAPLA2G4BPPARGALDH1A1 | |
| SCHEMBL4892227 | 0.77 | GLRA1 (0.49) | THRBTHRAGLRA1 | |
| SCHEMBL14097975 | 0.76 | THRB (0.64) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL4898263 | 0.75 | PLA2G2A (0.51) | THRBTHRAPLA2G4BRXRARARB | |
| SCHEMBL15270918 | 0.74 | THRB (0.71) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL4899221 | 0.74 | THRB (1.00) | THRBTHRAPLA2G4BPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRB 792/4885THRA 559/4885PLA2G4B 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.